Xin Lang Cai Jing·2025-09-26 09:25Core Viewpoint - Fosun Pharma's subsidiary plans to transfer 100% equity and debt of Shanghai Clone for a consideration not exceeding 1.256 billion yuan, aiming to focus on core business and enhance asset operation efficiency [1] Group 1: Transaction Details - The transaction involves a total consideration of up to 1.256 billion yuan [1] - The special fund plans to raise 547 million yuan, with Fosun Pharma contributing 54.6 million yuan, holding a 9.98% share of the fund [1] - After the transaction, Fosun Pharma will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operational purposes [1] Group 2: Strategic Intent - The proceeds from the transfer will be used for continued investment in innovative drug business [1]